Glioblastoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

GBM MCID: GLB002 MIFTS: 67	Glioblastoma (GBM) Categories: Cancer diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Glioblastoma

MalaCards integrated aliases for Glioblastoma:

IMPROVED

Name: Glioblastoma ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ²⁸ ⁵³ ⁵ ⁴³ ¹⁴ ⁷¹

Glioblastoma Multiforme ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ²⁸ ⁵³ ⁵ ¹⁴ ¹⁶ ⁷¹

Gbm ¹¹ ⁵⁸

Grade Iv Adult Astrocytic Tumor ¹¹

Primary Glioblastoma Multiforme ¹¹

Adult Glioblastoma Multiforme ¹¹

Spongioblastoma Multiforme ¹¹

Primary Glioblastoma ⁷¹

Adult Glioblastoma ⁷¹

Characteristics:

Inheritance:

Multigenic/multifactorial ⁵⁸

Prevelance:

1-9/100000 ⁵⁸

Age Of Onset:

All ages ⁵⁸

Age Of Death:

adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of eye, brain and other parts of central nervous system

Malignant neoplasm of brain

Malignant neoplasm: Brain, unspecified

Orphanet: ⁵⁸

Rare neurological diseases

External Ids:

Disease Ontology ¹¹ DOID:3068

MeSH ⁴³ D005909

NCIt ⁴⁹ C129295 C39750 C9094

SNOMED-CT ⁶⁸ 63634009

MESH via Orphanet ⁴⁴ D005909

ICD10 via Orphanet ³² C71.9

UMLS via Orphanet ⁷² C0017636 C1621958

Orphanet ⁵⁸ ORPHA360

SNOMED-CT via HPO ⁶⁹ 128613002 18963009 2032001 more

EFO ¹⁶ EFO_0000519

UMLS ⁷¹ C0017636 C0278878 C1514422 more

Sources

Summaries for Glioblastoma

GARD: ¹⁹ Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. Affected people may also experience other features depending on the size and location of the tumor. In most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1, Turcot syndrome and Li Fraumeni syndrome.

MalaCards based summary: Glioblastoma, also known as glioblastoma multiforme, is related to brain cancer and glioma, and has symptoms including headache and seizures. An important gene associated with Glioblastoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways is miRNAs involved in DNA damage response. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and eye, and related phenotypes are glioblastoma multiforme and abnormal cell morphology

Disease Ontology: ¹¹ A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

Orphanet: ⁵⁸ Glioblastomas are malignant astrocytic tumors (grade IV according to the WHO classification).

Wikipedia: ⁷⁵ Glioblastoma, previously known as glioblastoma multiforme (GBM), is one of the most aggressive types of... more...

Sources

Related Diseases for Glioblastoma

Diseases related to Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1269)

#	Related Disease	Score	Top Affiliating Genes
1	brain cancer	33.1	MSH2 MIR34A MIR296 MIR222 MIR221 MIR21
2	glioma	32.7	TP73-AS1 MIR34A MIR296 MIR222 MIR221 MIR21
3	high grade glioma	32.6	MIR221 MIR21 MALAT1 HOTAIRM1 HOTAIR GAS5
4	central nervous system cancer	32.1	MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
5	neuroblastoma	31.7	MIR34A MIR221 MIR21 MALAT1 HOTAIR GAS5
6	malignant astrocytoma	31.7	MIR34A MIR296 MIR222 MIR221 MIR21 AGAP2-AS1
7	medulloblastoma	31.6	MSH2 MIR34A MIR326 MIR221 MIR182 MIR17HG
8	melanoma	31.5	MIR34A MIR222 MIR221 MIR21 MIR182 MIR137
9	b-cell lymphoma	31.5	MIR17HG MALAT1 HOTAIR GAS5
10	lung cancer	31.4	TP73-AS1 NOS2 MSH2 MIR451A MIR34A MIR296
11	hematologic cancer	31.4	MSH2 MIR34A MIR222 MIR221 MIR21
12	hepatocellular carcinoma	31.3	TP73-AS1 NOS2 MSH2 MIR34A MIR222 MIR221
13	leukemia, acute lymphoblastic	31.3	MSH2 MIR451A MIR222 MIR221 MIR21
14	leukemia, acute myeloid	31.3	MIR451A MIR34A MIR326 MIR296 MIR222 MIR221
15	colorectal cancer	31.2	NOS2 MSH2 MIR451A MIR34A MIR296 MIR222
16	breast cancer	31.2	TP73-AS1 NOS2 MSH2 MIR451A MIR34A MIR222
17	lung cancer susceptibility 3	31.2	MIR296 MIR21 MIR182 MALAT1 HOTAIR GAS5
18	kidney cancer	31.1	MIR221 MIR21 MIR182 MALAT1 HOTAIR GAS5
19	central nervous system disease	31.1	MIR34A MIR222 MIR221 MIR21
20	ovarian cancer	31.1	MSH2 MIR34A MIR296 MIR222 MIR221 MIR21
21	prostate cancer	31.1	MSH2 MIR34A MIR296 MIR222 MIR221 MIR21
22	renal cell carcinoma, nonpapillary	31.0	MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
23	small cell cancer of the lung	31.0	MIR21 MALAT1 HOTAIR
24	bladder cancer	31.0	MSH2 MIR222 MIR221 MIR21 MALAT1 HOTAIR
25	diffuse large b-cell lymphoma	31.0	MIR222 MIR221 MIR21 MIR17HG HOTAIR
26	head and neck cancer	31.0	MIR34A MIR296 MIR222 MIR221 MIR21 GAS5
27	cellular ependymoma	31.0	MSH2 HOTAIR
28	esophageal cancer	31.0	MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
29	retinitis pigmentosa 11	30.9	MIR296 MIR182 HOTAIRM1 HOTAIR GAS5
30	pancreatic cancer	30.9	MSH2 MIR34A MIR222 MIR221 MIR21 MALAT1
31	thyroid carcinoma	30.8	MALAT1 HOTAIR GAS5
32	cervical cancer	30.8	MIR34A MIR221 MIR21 MALAT1 HOTAIR GAS5
33	hypertension, essential	30.8	NOS2 MIR34A MIR296 MIR222 MIR221 MIR21
34	myeloma, multiple	30.8	TP73-AS1 MIR221 MIR21 MALAT1 HOTAIR GAS5
35	leukemia, chronic lymphocytic	30.7	MIR34A MIR221 MIR21 MIR182 MIR17HG
36	spinal disease	30.6	MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
37	esophagus squamous cell carcinoma	30.6	TP73-AS1 MIR296 MALAT1 HOTAIR GAS5
38	gastric cancer	30.6	MSH2 MIR451A MIR34A MIR222 MIR221 MIR21
39	thyroid cancer, nonmedullary, 1	30.6	MIR222 MIR221 MALAT1 HOTAIR
40	rectum cancer	30.6	MSH2 MIR221 MIR21
41	muscular dystrophy, duchenne type	30.6	MIR34A MIR222 MIR221 MIR21
42	nervous system disease	30.5	NOS2 MIR34A MIR296 MIR222 MIR221 MIR21
43	bone disease	30.5	MIR34A MIR222 MIR221 MIR21
44	nasopharyngeal carcinoma	30.4	MIR296 MIR21 MALAT1 HOTAIR GAS5
45	pancreatic ductal adenocarcinoma	30.4	MIR34A MIR222 MIR221 MIR21 MALAT1 HOTAIRM1
46	thoracic cancer	30.4	MIR34A MIR296 MIR222 MIR221 MIR21 MIR182
47	lymphatic system disease	30.4	MIR34A MIR222 MIR221 MIR21 MIR182
48	ovarian epithelial cancer	30.1	MALAT1 HOTAIR
49	mantle cell lymphoma	29.7	MIR17HG MALAT1 GAS5
50	glioma susceptibility 1	11.8

Graphical network of the top 20 diseases related to Glioblastoma:

Sources

Symptoms & Phenotypes for Glioblastoma

Human phenotypes related to Glioblastoma:

³⁰ ⁵⁸ (show all 18)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	glioblastoma multiforme ³⁰	Obligate (100%)		HP:0012174
2	abnormal cell morphology ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0025461
3	muscle weakness ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001324
4	fatigue ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012378
5	headache ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002315
6	visual loss ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000572
7	abnormal corpus callosum morphology ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001273
8	language impairment ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002463
9	paralysis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003470
10	cerebral edema ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002181
11	emotional lability ³⁰	Frequent (33%)		HP:0000712
12	memory impairment ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002354
13	seizure ³⁰	Occasional (7.5%)		HP:0001250
14	seizures ⁵⁸		Occasional (29-5%)
15	abnormality of the cerebral white matter ⁵⁸		Frequent (79-30%)
16	abnormality of nervous system physiology ⁵⁸		Frequent (79-30%)
17	mood changes ⁵⁸		Frequent (79-30%)
18	glioblastoma ⁵⁸		Obligate (100%)

UMLS symptoms related to Glioblastoma:

headache; seizures

Sources

Drugs & Therapeutics for Glioblastoma

Drugs for Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 523)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Trametinib

Approved

Phase 4

871700-17-3

11707110

Dabrafenib

Approved, Investigational

Phase 4

1195765-45-7

44462760

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Citalopram

Approved

Phase 2, Phase 3

59729-32-7, 59729-33-8

2771

Meloxicam

Approved, Vet_approved

Phase 2, Phase 3

71125-38-7

54677470 5281106

Leflunomide

Approved, Investigational

Phase 3

75706-12-6

3899

Hydroxyurea

Approved

Phase 3

127-07-1

3657

Hydroxychloroquine

Approved

Phase 2, Phase 3

118-42-3

3652

Valproic acid

Approved, Investigational

Phase 3

99-66-1

3121

Tofacitinib

Approved, Investigational

Phase 3

477600-75-2

9926791

Etoposide

Approved

Phase 3

33419-42-0

36462

Procarbazine

Approved, Investigational

Phase 3

671-16-9

4915

Vincristine

Approved, Investigational

Phase 3

2068-78-2, 57-22-7

5978

Lomustine

Approved, Investigational

Phase 3

13010-47-4

3950

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Fluorouracil

Approved

Phase 2, Phase 3

51-21-8

3385

Dopamine

Approved

Phase 3

62-31-7, 51-61-6

681

Duloxetine

Approved

Phase 3

136434-34-9, 116539-59-4

60835

Norepinephrine

Approved

Phase 3

51-41-2

439260

Ascorbic acid

Approved, Nutraceutical

Phase 3

50-81-7

54676860 54670067 5785

Vitamin A

Approved, Nutraceutical, Vet_approved

Phase 3

2052-63-3, 22737-97-9, 22737-96-8, 68-26-8

9904001 9947823 5280382 445354

Dexetimide

Withdrawn

Phase 2, Phase 3

21888-98-2

30843

Nimotuzumab

Investigational

Phase 3

780758-10-3

Rindopepimut

Investigational

Phase 3

1108208-65-6

Semustine

Experimental, Investigational

Phase 3

13909-09-6

5198

GDC-0084

Investigational

Phase 2, Phase 3

1382979-44-3

57384863

Veliparib

Investigational

Phase 2, Phase 3

912444-00-9

11960529

Dianhydrogalactitol

Investigational

Phase 3

23261-20-3

Trabedersen

Investigational

Phase 3

925681-61-4

interferons

Phase 3

Interferon-alpha

Phase 3

Imatinib Mesylate

Phase 3

220127-57-1

Anesthetics

Phase 3

Anticonvulsants

Phase 3

Psychotropic Drugs

Phase 3

Neurotransmitter Agents

Phase 3

Poly(ADP-ribose) Polymerase Inhibitors

Phase 2, Phase 3

Etoposide phosphate

Phase 3

16760419

Micronutrients

Phase 3

Vitamins

Phase 3

Trace Elements

Phase 3

Pharmaceutical Solutions

Phase 3

Protective Agents

Phase 3

Antioxidants

Phase 3

Analgesics

Phase 3

Retinol palmitate

Phase 3

Dopamine Agents

Phase 3

Immunoconjugates

Phase 3

Antidepressive Agents

Phase 3

Interventional clinical trials:

(show top 50) (show all 1518)

#	Name	Status	NCT ID	Phase	Drugs
1	A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)	Completed	NCT00686725	Phase 4	Temozolomide
2	Pilot Study of Resection and GammaTile Followed by Concomitant External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant in Newly Diagnosed Glioblastoma (GBM)	Recruiting	NCT05342883	Phase 4
3	An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)	Recruiting	NCT03975829	Phase 4	dabrafenib;trametinib
4	A Single Center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of Neoadjuvant and Adjuvant Pembrolizumab on Top of Standard Chemo-Radiotherapy (Stupp Protocol) in Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme (GBM).	Not yet recruiting	NCT05235737	Phase 4	Pembrolizumab
5	A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient	Terminated	NCT01756729	Phase 4
6	A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma	Unknown status	NCT03633552	Phase 3	Temozolomide
7	The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients	Unknown status	NCT02623231	Phase 2, Phase 3	Escitalopram;placebo
8	PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA	Unknown status	NCT01308632	Phase 2, Phase 3	Temozolamide, irinotecan
9	Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional	Unknown status	NCT01811121	Phase 3	5-aminolévulinique acid (5-ALA);Placebo
10	Proteome-based Personalized Immunotherapy of Malignant Brain Tumors	Unknown status	NCT01759810	Phase 2, Phase 3
11	A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas	Unknown status	NCT01765088	Phase 3	Temozolomide;α-IFN
12	Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma	Unknown status	NCT01656980	Phase 3	Carmustine
13	A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients	Completed	NCT00482677	Phase 3	temozolomide
14	A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse	Completed	NCT00003293	Phase 3	leflunomide;procarbazine hydrochloride
15	Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial	Completed	NCT00224978	Phase 3	Chloroquine
16	PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence	Completed	NCT00076986	Phase 3	IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
17	A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy	Completed	NCT00068952	Phase 3	Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
18	Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study	Completed	NCT00006353	Phase 3	temozolomide
19	A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme	Completed	NCT01450449	Phase 3
20	Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV	Completed	NCT00753246	Phase 3	nimotuzumab
21	A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme	Completed	NCT00088400	Phase 3	TransMID
22	A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma	Completed	NCT00017147	Phase 3	carmustine;O6-Benzylguanine
23	A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME	Completed	NCT00002545	Phase 3	carmustine
24	A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM	Completed	NCT00379470	Phase 3
25	Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma	Completed	NCT00154375	Phase 3	Imatinib mesylate;Hydroxyurea
26	A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma	Completed	NCT03722355	Phase 3	Carmustine
27	A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.	Completed	NCT00916409	Phase 3	Temozolomide
28	Radiotherapy for Malignant Astrocytomas in the Elderly	Completed	NCT00430911	Phase 3	Radiotherapy
29	Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma	Completed	NCT01290939	Phase 3	lomustine
30	An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma	Completed	NCT01480479	Phase 3	Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
31	Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma	Completed	NCT00884741	Phase 3	Temozolomide
32	DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial	Completed	NCT02678975	Phase 2, Phase 3	Disulfiram;Alkylating Agents
33	A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)	Completed	NCT02617589	Phase 3	Nivolumab;Temozolomide
34	Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients	Completed	NCT01149109	Phase 3	Temozolomide and lomustine;Temozolomide
35	A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone	Completed	NCT00777153	Phase 3	Cediranib;Lomustine Chemotherapy;Placebo Cediranib
36	A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)	Completed	NCT02573324	Phase 2, Phase 3	Temozolomide;ABT-414;Placebo for ABT-414
37	Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma	Completed	NCT00304031	Phase 3	Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
38	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma	Completed	NCT00943826	Phase 3	Bevacizumab;Temozolomide;Placebo
39	A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma	Completed	NCT00335075	Phase 3	Temozolomide;Semustine
40	Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma	Completed	NCT00295815	Phase 3	enzastaurin;lomustine
41	Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea	Completed	NCT00807027	Phase 3	Activated T lymphocyte(Immuncell-LC)
42	Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial	Completed	NCT01805453	Phase 3	Losartan;Placebo
43	Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma	Completed	NCT01364064	Phase 3	TMZ
44	Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC)	Completed	NCT00689221	Phase 3	Cilengitide;Temozolomide
45	A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma	Completed	NCT02511405	Phase 3	VB-111 + bevacizumab;Bevacizumab
46	Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem)	Completed	NCT01502241	Phase 3	Temozolomide
47	Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma	Completed	NCT00820963	Phase 3	temozolomide
48	A Phase III Randomized Trial of Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (Avastin) With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed Glioblastoma (GBM)	Recruiting	NCT05271240	Phase 3	Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation;Temozolomide and Radiation Alone
49	A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme: the STELLAR Study	Recruiting	NCT03025893	Phase 2, Phase 3	Sunitinib;Lomustine
50	A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)	Recruiting	NCT02685605	Phase 3	Temozolomide

Search NIH Clinical Center for Glioblastoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Carmustine

Cochrane evidence based reviews: glioblastoma

Sources

Genetic Tests for Glioblastoma

Genetic tests related to Glioblastoma:

#	Genetic test	Affiliating Genes
1	Glioblastoma ²⁸
2	Glioblastoma Multiforme ²⁸

Sources

Anatomical Context for Glioblastoma

Organs/tissues related to Glioblastoma:

MalaCards : Brain, T Cells, Eye, Myeloid, Spinal Cord, Bone Marrow, Endothelial

Sources

Publications for Glioblastoma

Articles related to Glioblastoma:

(show top 50) (show all 33846)

#	Title	Authors	PMID	Year
1	MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. ⁵³ ⁶² ⁴⁶	Li Y...Abounader R	19773441	2009
2	miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. ⁵³ ⁶² ⁴⁶	Silber J...Hodgson JG	18577219	2008
3	Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. ⁵³ ⁶² ⁴⁶	Gillies JK...Lorimer IA	17721077	2007
4	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
5	MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. ⁶² ⁴⁶	Godlewski J...Lawler SE	20227367	2010
6	MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. ⁶² ⁴⁶	Li Y...Yu H	19559015	2009
7	miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. ⁶² ⁴⁶	Conti A...Tomasello F	19159078	2009
8	Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). ⁶² ⁴⁶	Lukiw WJ...Culicchia F	18759060	2009
9	MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. ⁶² ⁴⁶	Chen Y...Peng X	19013014	2008
10	MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. ⁶² ⁴⁶	Gal H...Givol D	18765229	2008
11	MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. ⁶² ⁴⁶	Papagiannakopoulos T...Kosik KS	18829576	2008
12	Extensive modulation of a set of microRNAs in primary glioblastoma. ⁶² ⁴⁶	Ciafre SA...Farace MG	16039986	2005
13	MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. ⁶² ⁴⁶	Chan JA...Kosik KS	16024602	2005
14	Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. ⁵³ ⁶²	Kuan CT...Bigner DD	19937796	2010
15	Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells. ⁵³ ⁶²	Puli S...Bhushan A	20177775	2010
16	miR-182 as a prognostic marker for glioma progression and patient survival. ⁴⁶	Jiang L...Li J	20472885	2010
17	Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. ⁵³ ⁶²	Li GH...Wang DL	20514402	2010
18	New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. ⁵³ ⁶²	Lopez-Gines C...Cerda-Nicolas M	20305620	2010
19	Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. ⁵³ ⁶²	Costa BM...Reis RM	20428822	2010
20	Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. ⁵³ ⁶²	Jin F...Zhao HY	20388502	2010
21	IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. ⁵³ ⁶²	Li R...Zhang J	20428809	2010
22	Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells. ⁵³ ⁶²	Duhem-Tonnelle V...Sharif A	20467331	2010
23	An unusual loss of EGFR gene copy in glioblastoma multiforme in a child: a case report and analysis of a successfully derived HGG-02 cell line. ⁵³ ⁶²	Veselska R...Sterba J	20195615	2010
24	Amplicons on chromosome 12q13-21 in glioblastoma recurrences. ⁵³ ⁶²	Fischer U...Meese E	19839052	2010
25	Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. ⁵³ ⁶²	Coulibaly B...Figarella-Branger D	20303140	2010
26	Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. ⁵³ ⁶²	Karayan-Tapon L...Gratas-Rabbia-Re C	19841865	2010
27	Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells. ⁵³ ⁶²	Pucer A...Lah TT	20302512	2010
28	Differential expression and cellular distribution of gamma-tubulin and betaIII-tubulin in medulloblastomas and human medulloblastoma cell lines. ⁵³ ⁶²	Caracciolo V...Katsetos CD	20162618	2010
29	Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. ⁵³ ⁶²	Pistollato F...Basso G	20309962	2010
30	FasL gene knock-down therapy enhances the antiglioma immune response. ⁵³ ⁶²	Jansen T...Olivi A	20406899	2010
31	Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. ⁵³ ⁶²	Gaspar N...Workman P	20457619	2010
32	Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. ⁵³ ⁶²	De Jesus ML...Callado LF	20307616	2010
33	Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. ⁵³ ⁶²	Garcia-Navarrete R...Sotelo J	19856144	2010
34	Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. ⁵³ ⁶²	Yoshida Y...Hamada J	19810093	2010
35	Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. ⁵³ ⁶²	He H...Conrad CA	20199106	2010
36	Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. ⁵³ ⁶²	Jung TY...Lee KH	20372840	2010
37	Integrin alpha 6 regulates glioblastoma stem cells. ⁵³ ⁶²	Lathia JD...Rich JN	20452317	2010
38	The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. ⁵³ ⁶²	Yoshida Y...Hamada J	19937366	2010
39	Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. ⁵³ ⁶²	Bobola MS...Silber JR	20457618	2010
40	Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. ⁵³ ⁶²	Gessi S...Borea PA	20096265	2010
41	The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. ⁵³ ⁶²	Bleeker FE...Van Noorden CJ	20127344	2010
42	Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. ⁵³ ⁶²	Bose D...Ellis LM	20171141	2010
43	Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. ⁵³ ⁶²	Yang F...Jove R	20371721	2010
44	Farnesyl diphosphate synthase attenuates paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells. ⁵³ ⁶²	Woo IS...Seo HG	20298756	2010
45	Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. ⁵³ ⁶²	Dasari VR...Rao JS	20436671	2010
46	Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. ⁵³ ⁶²	Kim EL...Giese A	20308316	2010
47	Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. ⁵³ ⁶²	Nasarre C...Bagnard D	20140015	2010
48	Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. ⁵³ ⁶²	Zuccoli G...Seyfried TN	20412570	2010
49	Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. ⁵³ ⁶²	Custodio A...Perez-Segura P	20462843	2010
50	A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu. ⁵³ ⁶²	Burden-Gulley SM...Brady-Kalnay SM	20360941	2010

Sources

Genes for Glioblastoma

Genes related to Glioblastoma (10 elite genes):

(show top 50) (show all 315)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIR21	MicroRNA 21	RNA Gene	420.7	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18829576 16039986
2	MIR221	MicroRNA 221	RNA Gene	418.79	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	17721077 16039986
3	MIR222	MicroRNA 222	RNA Gene	418.33	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	17721077 16039986
4	MSH2	MutS Homolog 2	Protein Coding	417.6	Pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12754350 12582944
5	MIR34A	MicroRNA 34a	RNA Gene	367.49	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19773441
6	MIR296	MicroRNA 296	RNA Gene	367.19	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18977327
7	MIR137	MicroRNA 137	RNA Gene	364.12	Causal ⁴⁶ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	18577219
8	MIR182	MicroRNA 182	RNA Gene	363.47	Causal ⁴⁶ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	20472885
9	MIR326	MicroRNA 326	RNA Gene	363.01	Causal ⁴⁶ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	19955368
10	MIR451A	MicroRNA 451a	RNA Gene	354.73	Causal ⁴⁶ DISEASES inferred ¹⁴	18765229
11	GLIDR	Glioblastoma Down-Regulated RNA	RNA Gene	170.7	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name (show sections)	23726844
12	NOS2	Nitric Oxide Synthase 2	Protein Coding	166.14	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18820242 8742473 10769671 (more) 10369188 14676405 9252671 15088099 7581489 7531687 11465394 11182788 7528267 11554386
13	LINC02604	Long Intergenic Non-Protein Coding RNA 2604	RNA Gene	165.14	Experimental evidence: Expression ³⁷ GeneCards inferred via : Publications Gene name (show sections)	29296221
14	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	164.07	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	24203894 25428914 25823657 (more) 26111795 26943771 27306825 28926136
15	MIR17HG	MiR-17-92a-1 Cluster Host Gene	RNA Gene	163.36	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	27229531
16	GAS5	Growth Arrest Specific 5	RNA Gene	163.15	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	23726844
17	HOTAIRM1	HOXA Transcript Antisense RNA, Myeloid-Specific 1	RNA Gene	162.93	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	26111795 26337623
18	TP73-AS1	TP73 Antisense RNA 1	RNA Gene	162.63	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	23726844 26337623
19	AGAP2-AS1	AGAP2 Antisense RNA 1	RNA Gene	162.27	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	26337623
20	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	162.01	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	25772239 29202181 29479863
21	DGCR5	DiGeorge Syndrome Critical Region Gene 5	RNA Gene	160.2	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴ ¹⁴	26111795
22	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	157.42	Experimental evidence: Regulation ³⁷ GeneCards inferred via : Publications (show sections)	16707459 20380817 25561975 (more) 26274999
23	XIST	X Inactive Specific Transcript	RNA Gene	155.91	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25578780
24	TUG1	Taurine Up-Regulated 1	Protein Coding	155.7	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27345398
25	HIF1A-AS2	HIF1A Antisense RNA 2	RNA Gene	155.39	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27264189
26	CYTOR	Cytoskeleton Regulator RNA	RNA Gene	155.17	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26337623
27	MCM3AP-AS1	MCM3AP Antisense RNA 1	RNA Gene	155.16	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27229531
28	MIR155HG	MIR155 Host Gene	RNA Gene	155.16	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26337623
29	PART1	Prostate Androgen-Regulated Transcript 1	RNA Gene	154.88	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	23726844
30	MIAT	Myocardial Infarction Associated Transcript	RNA Gene	154.87	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	23726844
31	SNHG7	Small Nucleolar RNA Host Gene 7	RNA Gene	154.71	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	29360452
32	PCAT1	Prostate Cancer Associated Transcript 1	RNA Gene	154.48	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	27306825
33	TUSC7	Tumor Suppressor Candidate 7	RNA Gene	154.46	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	29397407
34	BCYRN1	Brain Cytoplasmic RNA 1	RNA Gene	154.42	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	25561975
35	RAMP2-AS1	RAMP2 Antisense RNA 1	RNA Gene	154.31	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27784795
36	HOXA-AS3	HOXA Cluster Antisense RNA 3	RNA Gene	154.3	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	25561975
37	GAPLINC	Gastric Adenocarcinoma Associated, Positive CD44 Regulator, Long Intergenic Non-Coding RNA	RNA Gene	154.18	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27270310
38	PWAR5	Prader Willi/Angelman Region RNA 5	RNA Gene	154.11	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	23726844
39	LINC01116	Long Intergenic Non-Protein Coding RNA 1116	RNA Gene	154.1	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28423669
40	CNTN2	Contactin 2	Protein Coding	154.02	LncRNADisease ³⁷ DISEASES inferred ¹⁴	27432080
41	ANKH	ANKH Inorganic Pyrophosphate Transport Regulator	Protein Coding	153.96	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25378224
42	LINC00689	Long Intergenic Non-Protein Coding RNA 689	RNA Gene	153.87	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26337623
43	APTR	Alu-Mediated CDKN1A/P21 Transcriptional Regulator	RNA Gene	153.81	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24748121
44	WEE2-AS1	WEE2 Antisense RNA 1	RNA Gene	153.81	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25378224
45	MEG3	Maternally Expressed 3	RNA Gene	153.58	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	22234798 25378224 26111795 (more) 27306825
46	NCRUPAR	Non-Protein Coding RNA, Upstream Of F2R/PAR1	RNA Gene	153.25	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	25561975
47	LINC00963	Long Intergenic Non-Protein Coding RNA 963	RNA Gene	153.02	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25378224
48	LINC00173	Long Intergenic Non-Protein Coding RNA 173	RNA Gene	152.93	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26337623
49	LINC00572	Long Intergenic Non-Protein Coding RNA 572	RNA Gene	150	Experimental evidence: Regulation ³⁷	25378224
50	LINC00663	Long Intergenic Non-Protein Coding RNA 663	RNA Gene	150	Experimental evidence: Regulation ³⁷	26743782

Sources

Variations for Glioblastoma

ClinVar genetic disease variations for Glioblastoma:

IMPROVED

⁵ (show top 50) (show all 133)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	H3-3A	NM_002107.7(H3-3A):c.103G>A (p.Gly35Arg)	SNV	Other	438766	rs1553260624	GRCh37: 1:226252155-226252155 GRCh38: 1:226064454-226064454
2	MED12	NM_005120.3(MED12):c.5980C>T (p.Arg1994Trp)	SNV	Other	438772	rs1556339256	GRCh37: X:70357729-70357729 GRCh38: X:71137879-71137879
3	BCOR	NM_001123385.2(BCOR):c.3883_3884del (p.Leu1296fs)	MICROSAT	Other	284290	rs886042842	GRCh37: X:39922288-39922289 GRCh38: X:40063035-40063036
4	MSH2	NM_000251.3(MSH2):c.1958_1965del (p.Asn653fs)	DEL	Pathogenic	590849	rs1558518449	GRCh37: 2:47702360-47702367 GRCh38: 2:47475221-47475228
5	SLX4	NM_032444.4(SLX4):c.859_860del (p.Ser287fs)	DEL	Likely Pathogenic	620592	rs1567176006	GRCh37: 16:3652209-3652210 GRCh38: 16:3602208-3602209
6	DNMT3A	NM_022552.5(DNMT3A):c.2710C>T (p.Pro904Ser)	SNV	Likely Pathogenic	635110	rs1558650888	GRCh37: 2:25457177-25457177 GRCh38: 2:25234308-25234308
7	PIK3CA	NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)	SNV	Likely Pathogenic Likely Pathogenic	13655	rs104886003	GRCh37: 3:178936091-178936091 GRCh38: 3:179218303-179218303
8	MTOR	NM_004958.4(MTOR):c.4448G>A (p.Cys1483Tyr)	SNV	Likely Pathogenic Likely Pathogenic	376453	rs786205165	GRCh37: 1:11217230-11217230 GRCh38: 1:11157173-11157173
9	MTOR	NM_004958.4(MTOR):c.4447T>C (p.Cys1483Arg)	SNV	Likely Pathogenic	374796	rs1057519914	GRCh37: 1:11217231-11217231 GRCh38: 1:11157174-11157174
10	PIK3CA	NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)	SNV	Likely Pathogenic Likely Pathogenic	13652	rs121913279	GRCh37: 3:178952085-178952085 GRCh38: 3:179234297-179234297
11	TP53	NM_000546.6(TP53):c.743G>A (p.Arg248Gln)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	12356	rs11540652	GRCh37: 17:7577538-7577538 GRCh38: 17:7674220-7674220
12	ATM, C11orf65	NM_000051.4(ATM):c.8535G>A (p.Trp2845Ter)	SNV	Likely Pathogenic	555284	rs1555138291	GRCh37: 11:108216586-108216586 GRCh38: 11:108345859-108345859
13	PIK3CA	NM_006218.4(PIK3CA):c.113G>A (p.Arg38His)	SNV	Likely Pathogenic Likely Pathogenic	376492	rs772110575	GRCh37: 3:178916726-178916726 GRCh38: 3:179198938-179198938
14	PIK3CA	NM_006218.4(PIK3CA):c.1637A>T (p.Gln546Leu)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	375899	rs397517201	GRCh37: 3:178936095-178936095 GRCh38: 3:179218307-179218307
15	CREBBP	NM_004380.3(CREBBP):c.4336C>G (p.Arg1446Gly)	SNV	Likely Pathogenic Likely Pathogenic	376388	rs398124146	GRCh37: 16:3788618-3788618 GRCh38: 16:3738617-3738617
16	PIK3CA	NM_006218.4(PIK3CA):c.1031T>C (p.Val344Ala)	SNV	Likely Pathogenic Likely Pathogenic	376499	rs1057519941	GRCh37: 3:178921549-178921549 GRCh38: 3:179203761-179203761
17	PIK3CA	NM_006218.4(PIK3CA):c.1357G>C (p.Glu453Gln)	SNV	Likely Pathogenic Likely Pathogenic	376471	rs1057519925	GRCh37: 3:178928079-178928079 GRCh38: 3:179210291-179210291
18	PIK3CA	NM_006218.4(PIK3CA):c.333G>C (p.Lys111Asn)	SNV	Likely Pathogenic	376483	rs1057519934	GRCh37: 3:178916946-178916946 GRCh38: 3:179199158-179199158
19	PIK3CA	NM_006218.4(PIK3CA):c.1034A>T (p.Asn345Ile)	SNV	Likely Pathogenic Likely Pathogenic	376488	rs1057519938	GRCh37: 3:178921552-178921552 GRCh38: 3:179203764-179203764
20	PIK3CA	NM_006218.4(PIK3CA):c.112C>G (p.Arg38Gly)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	376496	rs749415085	GRCh37: 3:178916725-178916725 GRCh38: 3:179198937-179198937
21	PIK3CA	NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu)	SNV	Likely Pathogenic Likely Pathogenic	13654	rs121913286	GRCh37: 3:178936094-178936094 GRCh38: 3:179218306-179218306
22	EGFR	NM_005228.5(EGFR):c.866C>T (p.Ala289Val)	SNV	Likely Pathogenic Likely Pathogenic	376209	rs149840192	GRCh37: 7:55221822-55221822 GRCh38: 7:55154129-55154129
23	MYCNOS, MYCN	NM_005378.6(MYCN):c.131C>T (p.Pro44Leu)	SNV	Likely Pathogenic	376460	rs1057519919	GRCh37: 2:16082317-16082317 GRCh38: 2:15942195-15942195
24	FBXW7	NM_001349798.2(FBXW7):c.1435C>G (p.Arg479Gly)	SNV	Likely Pathogenic	376422	rs747241612	GRCh37: 4:153247367-153247367 GRCh38: 4:152326215-152326215
25	EGFR	NM_005228.5(EGFR):c.322A>G (p.Arg108Gly)	SNV	Likely Pathogenic	376400	rs1057519888	GRCh37: 7:55211079-55211079 GRCh38: 7:55143386-55143386
26	PIK3CA	NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu)	SNV	Likely Pathogenic Likely Pathogenic	376487	rs1057519936	GRCh37: 3:178952072-178952072 GRCh38: 3:179234284-179234284
27	EGFR	NM_005228.5(EGFR):c.865_866delinsAA (p.Ala289Asn)	INDEL	Likely Pathogenic Likely Pathogenic	376397	rs1057519887	GRCh37: 7:55221821-55221822 GRCh38: 7:55154128-55154129
28	IDH1	NM_005896.4(IDH1):c.395G>T (p.Arg132Leu)	SNV	Likely Pathogenic Likely Pathogenic	375889	rs121913500	GRCh37: 2:209113112-209113112 GRCh38: 2:208248388-208248388
29	FBXW7	NM_001349798.2(FBXW7):c.1973G>A (p.Arg658Gln)	SNV	Likely Pathogenic	376427	rs759610249	GRCh37: 4:153244184-153244184 GRCh38: 4:152323032-152323032
30	EGFR	NM_005228.5(EGFR):c.2155G>T (p.Gly719Cys)	SNV	Likely Pathogenic	16611	rs28929495	GRCh37: 7:55241707-55241707 GRCh38: 7:55174014-55174014
31	PIK3CA	NM_006218.4(PIK3CA):c.1033A>C (p.Asn345His)	SNV	Likely Pathogenic	376490	rs1057519939	GRCh37: 3:178921551-178921551 GRCh38: 3:179203763-179203763
32	EGFR	NM_005228.5(EGFR):c.2156G>A (p.Gly719Asp)	SNV	Likely Pathogenic Likely Pathogenic	376075	rs121913428	GRCh37: 7:55241708-55241708 GRCh38: 7:55174015-55174015
33	PIK3R1	NM_181523.3(PIK3R1):c.1126G>C (p.Gly376Arg)	SNV	Likely Pathogenic	376065	rs1057519757	GRCh37: 5:67589138-67589138 GRCh38: 5:68293310-68293310
34	PIK3CA	NM_006218.4(PIK3CA):c.1359A>T (p.Glu453Asp)	SNV	Likely Pathogenic	376472	rs1057519926	GRCh37: 3:178928081-178928081 GRCh38: 3:179210293-179210293
35	PIK3CA	NM_006218.4(PIK3CA):c.331A>G (p.Lys111Glu)	SNV	Likely Pathogenic	376482	rs1057519933	GRCh37: 3:178916944-178916944 GRCh38: 3:179199156-179199156
36	FBXW7	NM_001349798.2(FBXW7):c.1436G>A (p.Arg479Gln)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	376419	rs866987936	GRCh37: 4:153247366-153247366 GRCh38: 4:152326214-152326214
37	PIK3CA	NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr)	SNV	Likely Pathogenic	376486	rs1057519937	GRCh37: 3:178952073-178952073 GRCh38: 3:179234285-179234285
38	PIK3CA	NM_006218.4(PIK3CA):c.1638G>T (p.Gln546His)	SNV	Likely Pathogenic	376491	rs1057519940	GRCh37: 3:178936096-178936096 GRCh38: 3:179218308-179218308
39	IDH1	NM_005896.4(IDH1):c.394C>A (p.Arg132Ser)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	375893	rs121913499	GRCh37: 2:209113113-209113113 GRCh38: 2:208248389-208248389
40	EGFR	NM_005228.5(EGFR):c.1793G>T (p.Gly598Val)	SNV	Likely Pathogenic Likely Pathogenic	376210	rs139236063	GRCh37: 7:55233043-55233043 GRCh38: 7:55165350-55165350
41	H3-3A	NM_002107.7(H3-3A):c.100G>C (p.Gly34Arg)	SNV	Likely Pathogenic	376434	rs1057519902	GRCh37: 1:226252152-226252152 GRCh38: 1:226064451-226064451
42	PIK3CA	NM_006218.4(PIK3CA):c.332A>G (p.Lys111Arg)	SNV	Likely Pathogenic	376484	rs1057519935	GRCh37: 3:178916945-178916945 GRCh38: 3:179199157-179199157
43	CREBBP	NM_004380.3(CREBBP):c.4337G>T (p.Arg1446Leu)	SNV	Likely Pathogenic Likely Pathogenic	376386	rs1057519884	GRCh37: 16:3788617-3788617 GRCh38: 16:3738616-3738616
44	POLE	NM_006231.4(POLE):c.1231G>T (p.Val411Leu)	SNV	Likely Pathogenic	376503	rs1057519945	GRCh37: 12:133250289-133250289 GRCh38: 12:132673703-132673703
45	EGFR	NM_005228.5(EGFR):c.865G>A (p.Ala289Thr)	SNV	Likely Pathogenic	376395	rs769696078	GRCh37: 7:55221821-55221821 GRCh38: 7:55154128-55154128
46	FGFR1	NM_023110.3(FGFR1):c.1968G>C (p.Lys656Asn)	SNV	Likely Pathogenic	376428	rs1057519897	GRCh37: 8:38272306-38272306 GRCh38: 8:38414788-38414788
47	PIK3CA	NM_006218.4(PIK3CA):c.1030G>A (p.Val344Met)	SNV	Likely Pathogenic	376498	rs1057519942	GRCh37: 3:178921548-178921548 GRCh38: 3:179203760-179203760
48	TP53	NM_000546.6(TP53):c.658T>A (p.Tyr220Asn)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	376688	rs530941076	GRCh37: 17:7578191-7578191 GRCh38: 17:7674873-7674873
49	MTOR	NM_004958.4(MTOR):c.6643T>A (p.Ser2215Thr)	SNV	Likely Pathogenic	376457	rs1057519917	GRCh37: 1:11184574-11184574 GRCh38: 1:11124517-11124517
50	PIK3CA	NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys)	SNV	Likely Pathogenic	376478	rs1057519929	GRCh37: 3:178916854-178916854 GRCh38: 3:179199066-179199066

Copy number variations for Glioblastoma from CNVD:

⁶ (show top 50) (show all 797)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	13315	1	1	117600000	Gain		Glioblastoma multiforme
2	13333	1	1	124300000	Gain		Glioblastoma multiforme
3	13339	1	1	124300000	Loss		Glioblastoma multiforme
4	13340	1	1	124300000	Loss		Glioblastoma multiforme
5	13341	1	1	124300000	Loss		Glioblastoma multiforme
6	13359	1	1	12600000	Gain		Glioblastoma multiforme
7	13365	1	1	16100000	Gain		Glioblastoma multiforme
8	13750	1	1	27800000	Loss		Glioblastoma multiforme
9	13758	1	1	28000000	Copy number		Glioblastoma
10	13761	1	1	28000000	Deletion		Glioblastoma multiforme
11	13763	1	1	28000000	Gain		Glioblastoma multiforme
12	13775	1	1	39600000	Loss		Glioblastoma multiforme
13	13792	1	1	51300000	Loss		Glioblastoma multiforme
14	13822	1	1	7200000	Deletion	MTHFR	Glioblastoma multiforme
15	14314	1	107000000	111600000	Gain		Glioblastoma multiforme
16	14414	1	107915304	108309068	amplification	VAV3	Glioblastoma multiforme
17	14609	1	109636509	109651136	Fusion	MYBPHL	Glioblastoma multiforme
18	15403	1	115061059	115084034	Fusion	CSDE1	Glioblastoma multiforme
19	16435	1	124300000	247249719	Gain		Glioblastoma multiforme
20	16436	1	124300000	247249719	Gain		Glioblastoma multiforme
21	16437	1	124300000	247249719	Gain		Glioblastoma multiforme
22	16444	1	124300000	247249719	Loss		Glioblastoma multiforme
23	16683	1	130300000	212100000	Gain	ATP2B4	Glioblastoma multiforme
24	19008	1	148161834	148166860	Copy number	SF3B4	Glioblastoma multiforme
25	19791	1	151370387	155734861	Gain	CLK2	Glioblastoma multiforme
26	20600	1	153272923	153289968	Fusion	DCST1	Glioblastoma multiforme
27	20612	1	153300000	154800000	Gain	RAB25	Glioblastoma multiforme
28	21114	1	156847119	156923130	Copy number	SPTA1	Glioblastoma multiforme
29	22041	1	16450831	16482564	Copy number	EPHA2	Glioblastoma multiforme
30	23682	1	172900000	185800000	Gain		Glioblastoma multiforme
31	24288	1	178190530	178346919	Fusion	CEP350	Glioblastoma multiforme
32	25428	1	189000000	197500000	Gain		Glioblastoma multiforme
33	25567	1	191357783	191486465	Fusion	CDC73	Glioblastoma multiforme
34	26137	1	197500000	205300000	Amplification	LRRN2	Glioblastoma multiforme
35	26138	1	197500000	205300000	Amplification	MDM4	Glioblastoma multiforme
36	26139	1	197500000	205300000	Amplification	MDM4	Glioblastoma multiforme
37	26142	1	197500000	205300000	Amplification	NFASC	Glioblastoma multiforme
38	26146	1	197500000	205300000	Amplificationlication	MDM2	Glioblastoma multiforme
39	26474	1	200429740	200554958	Truncation	LGR6	Glioblastoma multiforme
40	26515	1	200858000	202110000	Copy number	MDM4	Glioblastoma multiforme
41	26660	1	201942811	203355851	Amplification	MDM4	Glioblastoma multiforme
42	28554	1	223214607	229308654	Gain	ARF1	Glioblastoma multiforme
43	28555	1	223214607	229308654	Gain	WNT3A	Glioblastoma multiforme
44	29626	1	233890968	234060340	Fusion	LYST	Glioblastoma multiforme
45	30289	1	241700000	247249719	Amplification	AKT3	Glioblastoma multiforme
46	30312	1	241718157	242073207	Amplification	AKT3	Glioblastoma
47	30407	1	2429834	2447886	Fusion	PANK4	Glioblastoma multiforme
48	31747	1	30500000	171200000	Gain		Glioblastoma multiforme
49	32775	1	3928417	3978407	Deletion		Glioblastoma multiforme
50	32899	1	4028404	6333694	Deletion	AJAP1	Glioblastoma multiforme

Sources

Expression for Glioblastoma

Search GEO for disease gene expression data for Glioblastoma.

Sources

Pathways for Glioblastoma

Pathways directly related to Glioblastoma:

#	Pathway	Source
1	Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate	Reactome ⁶⁶

Pathways related to Glioblastoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	miRNAs involved in DNA damage response ⁷⁴	10.63	MIR222 MIR221 MIR21

Sources

GO Terms for Glioblastoma

Cellular components related to Glioblastoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.8	MIR326 MIR296 MIR222 MIR221 MIR21 MIR17HG
2	extracellular vesicle	GO:1903561	9.02	MIR451A MIR34A MIR222 MIR221 MIR21

Biological processes related to Glioblastoma according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell migration	GO:0030336	9.87	MIR451A MIR34A MIR21 MIR137
2	negative regulation of angiogenesis	GO:0016525	9.78	MIR34A MIR222 MIR21 MIR137
3	negative regulation of protein kinase B signaling	GO:0051898	9.73	MIR451A MIR34A MIR137
4	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.72	MIR222 MIR221 MIR21
5	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	9.7	MIR222 MIR221 MIR21
6	negative regulation of vascular associated smooth muscle cell proliferation	GO:1904706	9.69	MIR34A MIR182 MIR137
7	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.62	MIR222 MIR221 MIR21 MIR182
8	positive regulation of axon regeneration	GO:0048680	9.59	MIR222 MIR221
9	negative regulation of cell adhesion molecule production	GO:0060354	9.58	MIR222 MIR221
10	negative regulation by host of viral genome replication	GO:0044828	9.58	MIR222 MIR221
11	miRNA-mediated gene silencing	GO:0035195	9.55	MIR451A MIR34A MIR326 MIR296 MIR222 MIR221
12	negative regulation of xenobiotic detoxification by transmembrane export across the plasma membrane	GO:1905700	9.54	MIR451A MIR326
13	positive regulation of vascular associated smooth muscle cell migration	GO:1904754	9.54	MIR451A MIR221 MIR21
14	negative regulation of leukocyte adhesion to vascular endothelial cell	GO:1904995	9.49	MIR222 MIR221
15	negative regulation of hematopoietic stem cell proliferation	GO:1902034	9.46	MIR222 MIR221
16	negative regulation of vascular associated smooth muscle cell migration	GO:1904753	9.46	MIR34A MIR21 MIR182 MIR137
17	positive regulation of Schwann cell migration	GO:1900149	9.43	MIR221 MIR222
18	negative regulation of TRAIL-activated apoptotic signaling pathway	GO:1903122	9.4	MIR221 MIR222
19	positive regulation of Schwann cell proliferation involved in axon regeneration	GO:1905046	9.26	MIR222 MIR221
20	negative regulation of interleukin-21 production	GO:0032705	9.13	MIR222 MIR221 MIR21

Molecular functions related to Glioblastoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.43	MIR451A MIR34A MIR326 MIR296 MIR21 MIR137
2	mRNA base-pairing translational repressor activity	GO:1903231	9.28	MIR451A MIR34A MIR326 MIR296 MIR222 MIR221